Get the Stockscreener App
6.4324
7.18%
-0.5276
Acrivon Therapeutics Inc stock is traded at $6.4324, with a volume of 57,958.
It is down -7.18% in the last 24 hours and down -21.70% over the past month.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
See More
Previous Close:
$6.96
Open:
$6.91
24h Volume:
57,958
Relative Volume:
0.69
Market Cap:
$204.73M
Revenue:
-
Net Income/Loss:
$-69.00M
P/E Ratio:
-2.574
EPS:
-2.499
Net Cash Flow:
$-55.26M
1W Performance:
-21.51%
1M Performance:
-21.70%
6M Performance:
-27.33%
1Y Performance:
+66.07%
1-Day Range:
$6.25
$6.98
1-Week Range:
$6.25
$8.5399
52-Week Range:
$3.19
$11.90
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Name
Acrivon Therapeutics Inc
Sector
Industry
Phone
617-207-8979
Address
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ACRV | 6.4185 | 204.73M | 0 | -69.00M | -55.26M | -2.499 |
| VRTX | 467.64 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 761.02 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 564.78 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 230.25 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.63 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Apr-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Apr-20-23 | Initiated | H.C. Wainwright | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Dec-12-22 | Initiated | Jefferies | Buy |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
View All
Acrivon Therapeutics Inc Stock (ACRV) Latest News
Equities Analysts Offer Predictions for ACRV FY2024 Earnings - MarketBeat
We're Not Very Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate - Simply Wall St
Acrivon Therapeutics’ (ACRV) “Buy” Rating Reiterated at HC Wainwright - Defense World
BMO Capital Markets Cuts Acrivon Therapeutics (NASDAQ:ACRV) Price Target to $27.00 - Defense World
When (ACRV) Moves Investors should Listen - Stock Traders Daily
Acrivon Therapeutics Reports Promising Clinical Progress and Financial Results - TipRanks
Acrivon stock retains Outperform as BMO cuts target due to minor cash adjustments - Investing.com
Acrivon Therapeutics (NASDAQ:ACRV) Price Target Cut to $27.00 by Analysts at BMO Capital Markets - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Given Buy Rating at HC Wainwright - MarketBeat
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
Acrivon's Cancer Drug Shows 62.5% Response Rate; Reports $202.8M Cash Position | ACRV Stock News - StockTitan
Acrivon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.83 Average PT from Analysts - Defense World
Trend Tracker for (ACRV) - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update - Defense World
Acrivon Therapeutics' SWOT analysis: promising oncology pipeline faces market hurdles - Investing.com Canada
Acrivon Therapeutics' SWOT analysis: promising oncology pipeline faces market hurdles By Investing.com - Investing.com South Africa
(ACRV) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Promising Endometrial Cancer Trial Data Puts Acrivon In Focus - RTTNews
Biomea Fusion (NASDAQ:BMEA) & Acrivon Therapeutics (NASDAQ:ACRV) Financial Survey - Defense World
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific ConferencesHuman Proteome Organization World Congress and EORTC-NCI-AACR Symposiu - GlobeNewswire
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Drop in Short Interest - MarketBeat
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
(ACRV) Investment Analysis and Advice - Stock Traders Daily
Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline - Yahoo Finance
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Acrivon commences Phase 1 trial for cancer drug ACR-2316 - Investing.com
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - GlobeNewswire
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel - The Bakersfield Californian
Acrivon Therapeutics, Inc. Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - Marketscreener.com
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Shares Bought by Marshall Wace LLP - MarketBeat
Perceptive Advisors LLC Acquires 2,353,000 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - MarketBeat
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Expands By 24.3% - MarketBeat
Wall Street SWOT: Acrivon Therapeutics stock shows promise amid oncology challenges - Investing.com
The Potential Rise in the Price of ACM Research Inc (ACMR) following insiders activity - Knox Daily
Nippon Shinyaku buys $15 million of Capricor Therapeutics stock - Investing.com
Capricor Therapeutics price target raised to $25 from $12 at Maxim - TipRanks
Capricor stock surges on pipeline update (NASDAQ:CAPR) - Seeking Alpha
DRW Securities LLC Invests $287,000 in Arch Capital Group Ltd. (NASDAQ:ACGL) - Defense World
Capricor Therapeutics Shares Rise in Premarket on Plans to File Application for Deramiocel - MarketWatch
You might want to take a look at ACM Research Inc (ACMR) now - SETE News
When the Price of (ACRV) Talks, People Listen - Stock Traders Daily
Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains? - Yahoo Finance
Benjamin F. Edwards & Company Inc. Has $847,000 Stock Position in Arch Capital Group Ltd. (NASDAQ:ACGL) - Defense World
Ladenburg Thalmann Upgrades Acrivon Therapeutics Inc (ACRV) to a Buy from a Neutral - Knox Daily
Deeper Dive: Understanding Acrivon Therapeutics Inc (ACRV) Through its Various Ratios - The Dwinnex
Brighton Jones LLC Makes New Investment in Arch Capital Group Ltd. (NASDAQ:ACGL) - Defense World
Acrivon Therapeutics Inc (ACRV) produces promising results - US Post News
Mercer Global Advisors Inc. ADV Has $2.94 Million Holdings in Arch Capital Group Ltd. (NASDAQ:ACGL) - Defense World
ArriVent BioPharma, Inc.(NasdaqGM:AVBP) added to S&P Biotechnology Select Industry Index - Marketscreener.com
Acrivon Therapeutics Inc Stock (ACRV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acrivon Therapeutics Inc Stock (ACRV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 11 '24 |
Buy |
8.50 |
2,353,000 |
20,000,500 |
5,360,858 |
3.39%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):